Bezlotoxumab (BEZ) for Prevention of Clostridium Difficile Infection (CDI) Recurrence (rCDI): Outcomes in Patients with Substantial Renal Impairment (SRI)

BACKGROUND: CDI in patients with SRI is harder to treat and is associated with higher recurrence. MODIFY I/II found that BEZ, a monoclonal antibody against C. difficile toxin B, is superior to placebo (PBO) at preventing rCDI in patients receiving standard of care antibiotics (SoC). This post hoc an...

Descripción completa

Detalles Bibliográficos
Autores principales: Golan, Yoav, DuPont, Herbert L, Aldomiro, Fernando, Jensen, Erin H, Hanson, Mary E, Dorr, Mary Beth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630736/
http://dx.doi.org/10.1093/ofid/ofx163.962

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630736/
http://dx.doi.org/10.1093/ofid/ofx163.962

Ejemplares similares